KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Total Non-Current Liabilities (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Total Non-Current Liabilities for 14 consecutive years, with $2.9 billion as the latest value for Q1 2026.

  • For Q1 2026, Total Non-Current Liabilities rose 28.43% year-over-year to $2.9 billion; the TTM value through Mar 2026 reached $2.9 billion, up 28.43%, while the annual FY2025 figure was $3.0 billion, 27.22% up from the prior year.
  • Total Non-Current Liabilities hit $2.9 billion in Q1 2026 for Ionis Pharmaceuticals, down from $3.0 billion in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $3.0 billion in Q4 2025 and bottomed at $1.9 billion in Q3 2024.
  • Average Total Non-Current Liabilities over 5 years is $2.3 billion, with a median of $2.3 billion recorded in 2024.
  • Year-over-year, Total Non-Current Liabilities decreased 26.82% in 2024 and then rose 28.43% in 2026.
  • Ionis Pharmaceuticals' Total Non-Current Liabilities stood at $2.0 billion in 2022, then rose by 6.56% to $2.1 billion in 2023, then rose by 13.1% to $2.4 billion in 2024, then increased by 27.22% to $3.0 billion in 2025, then decreased by 2.54% to $2.9 billion in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $2.9 billion, $3.0 billion, and $2.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.